SlideShare a Scribd company logo
1 of 4
Download to read offline
www.geriatricsummit.com
BOOK BY 31ST MAY AND SAVE £300 / BOOK BY 28TH JUNE AND SAVE £100
Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
FEATURED SPEAKERS:WHY ATTEND THIS EVENT:
• Discover the benefits of performing clinical
trials in older people
• Identify the key challenges and
considerations when conducting clinical trials
in older people
• Address reasons for clinical trial retention
difficulties
• Discuss how modelling and simulation
along with new patient reporting systems
support clinical trials in older people
• Explore new market gaps and discover new
market strategy
• Focus on the EMA geriatric medicines
strategy
• Solange Rohou, Director of Regulatory Affairs,
AstraZeneca
• Barbro Westerholm, Member of Parliament, Sweden,
Liberal Party
Novartis
• Michael Richardson, VP International and QPPV EU
GPV&E, Bristol Myers Squibb
• Eva Bredberg, Director Global Clinical Pharmacology,
AstraZeneca
• Peter Crome, Professor, Department of Primary Care
and Population Health, University College London
• Anthea Tinker, Professor of Social Gerontology,
Kings College London
SMi Presents their Inaugural 16 - 17
SEPT
2013Marriott Hotel, Regents Park, London, UK
Geriatric Safe
Medicines Summit
• Florian Von Raison, Global Programme Head,
• Nina Barnett, Consultant Pharmacist,Northwest
• Philippe Guillet, Chief Geriatrician,TSU Ageing,
Sanofi R&D
London Hospitals Trust
Want to know how you
can get involved? Interested
in promoting your
pharmaceutical services
to this market?
Contact Margaret Mugema,
SMi Marketing on
+44 (0) 207 827 6072,
or email
mmugema@smi-online.co.uk
Register online at: www.geriatricsummit.com • Alternatively fax yo
• Pharmacovigilance Specialists
• QPPV
• Consultant Pharmacologist
• Recruitment and Retention
Managers
• Head of Medicine and Society
• Medical Advisor
WHO SHOULD ATTEND:
08.30 REGISTRATION & COFFEE
09.00 CHAIRMAN’S OPENING REMARKS:
Solange Rohou, Director of Regulatory Affairs, AstraZeneca
KEY NOTE
09.10 Patient Perspectives on Healthy Ageing
• Most important is to be regarded as a resource, to feel
needed
• Not to meet ageism/age discrimination
• Effective and safe treatment when in need
Barbro Westerholm, Member of Parliament, Sweden,
Liberal Party
Increasing the Representation of Older People in Clinical Trials
09:50 Representation of Older People in Clinical Trials:
Results and recommendations of the PREDICT Study
• The systematic reviews confirmed the continued unjustified
exclusion of older people from clinical trials and that
clinicians treating older people and other professional
believed that older people were disadvantaged as a result
• Focus groups held in the 9 participating countries confirmed
that older people and their countries supported a more
robust system for including older people in clinical trials
Peter Crome, Professor, University College London
10.30 MORNING COFFEE
11.00 Why do older people drop out of longitudinal health
studies and how can they be encouraged to continue to
participate?
• The evidence from longitudinal studies abut older people
who drop out of studies
• A case study of the Whitehall research on drop out including
what would encourage participation
• A personal perspective on involvement in 3 longitudinal
studies
Anthea Tinker, Professor of Gerontology, Kings College
London
Addressing Adherence Issues
11.40 What can we learn from non adherence in the Clinical
Trial
• Adherence as a key to achieve the therapeutic outcomes
• Reasons for non-adherence: a patient perspective
• Understanding non-adherence as a source for product
enhancement early on
Sven Stegemann, Director, Capsugel
12.20 NETWORKING LUNCH
13.30 A coaching approach to medication adherence
• Changing the consultation paradigm - the imperatives
• Practical and perceptual approaches to adherence
• Coaching and medication adherence
• Managing short consultations
Nina Lee Barnett, Consultant Pharmacist, Older People
North West London Hospitals Trust and E&SE England
Specialist Pharmacy Services
14.10 Are low treatment uptake rates due to polymorbidity
and polymedication issues: perspectives from the
osteoporosis treatment gap in France and the UK.
• Evolution of guidelines and clinical practices in the
management of osteoporosis
• Current osteoporosis guidelines and treatment gap
• Reasons for treatment decline, uptake and withdrawal
Jonathan Guillemot, Gerontologist, Kings College London
14.50 AFTERNOON TEA
15.20 Can elderly people use new technologies to record their
own data?
• Where are we with ePRO in general, and specifically with
elderly?
• What is our experience with elderly?
• What is to be considered in Clinical Trials with elderly when
they have unsupervised data collection?
• Case studies
Valdo Arnera, General Manager, PHT Corp
16.00 Formulation development of orally disintegrating
tablets: An opportunity to address swallowing
difficulties in geriatric patients
• The formulation approaches used to overcome medication
non adherence in geriatric patients and the paradigm of
patient-centered dosage forms
• The emerging pharmaceutical orally disintegrating dosage
forms and their significance in the increasingly ageing
society
• Various technologies and cost-effective strategies for orally
disintegrating tablet formulation
• Novel atomic force microscopy applications which provide an
insight into molecular aspects of orally disintegrating tablets
formulation development
Ali Al-Khattawi, Researcher in Pharmaceutical
Sciences/Drug Delivery, Aston University
16.40 Chairman’s Closing Remarks and Close of Day One
• Program Heads
• Clinical Trial Design
Manager
• Gerontologists
• Geriatrician
• Clinical Trials Manager
• Academics
DAY ONE | 16TH SEPTEMBER 2013 Geriatric Safe Medicines Summit
Supported by
• Research Scientists
• Pharmaceutical
regulators
• Stakeholders and those
with an interest in
Geriatric medicine
our registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711
DAY TWO | 17TH SEPTEMBER 2013
08.30 REGISTRATION & COFFEE
09.00 CHAIRMAN’S OPENING REMARKS:
Solange Rohou, Director of Regulatory Affairs, AstraZeneca
Improving Safety Within Geriatric Clinical Trials
09.10 Geriatric Syndromes: What are they?
Why do they matter?
• Old Old Adults (75+) is the fastest growing segment of
population
• Old Old subject to specific Geriatric Syndromes (Frailty,
Delirium,...), which change the way acute situations
manifest themselves (including drug effects and toxicities),
needing specific screening, diagnosis & treatment
approaches
09.50 Modelling & simulation to support evaluation of safety
and efficacy of drugs in older patients
• Strategic considerations in drug development regarding
the elderly
• Changes in PK and PD with age
• What value can M&S provide to improve understanding
of risk benefits in older people?
• Two examples from AstraZeneca
Eva Bredberg, Director Global Clinical Pharmacology,
AstraZeneca
10.30 MORNING COFFEE
11.00 What has been done since the revision of the ICH E7
guideline? The Companies' view
• The revision of ICH E7
• EFPIA interactions at the workshop organised by the EMA in
March 2012
• How to optimise clincial development in the elderly?
• What companies are planning/doing to collect data in this
special growing population
Solange Rohou, Director Regulatory Affairs, AstraZeneca
11.40 Early identification of co-morbidities and the challenges
of prescribing in this patient population due to drug-
drug interactions
• Cognitive impairment as a barrier to treatment
• The impact of co-mobidities on a Clinical Trial
• Developing effective patient reporting systems as a way to
improve patient compliance
Mark Baxter, Geriatric Consultant, Spire Sussex Hospital
12.20 NETWORKING LUNCH
Importance of Guidance on Medical Research
in Geriatric Patients
13.30 Proposal for guidance on medical research for and with
older people in Europe
• There is an evident lack of consistent ethical guidance on
medical research for and with older people in Europe
• Workshops with stakeholders from academia, investigators,
patient representatives and pharma were held to develop
a consensus on principals
• The aim of the guidance is to facilitate clinical research for
and with the older patient population
Florian Von Raison, Global Program Head, Novartis
Pharma
14.10 Information for rational drug prescribing to older
patients - from pre-authorisation to post-marketing
• Older patients in pre-authorisation trials – number,
exclusion criteria and representability
• Available information for adequate prescribing to older
patients – product information and handbooks
• What information for adequate prescribing about older
patients is needed? – views of clinical and non-clinical
professionals
Erna Beers, MD, Clinical Pharmacologist, UMC Utrecht
14.50 AFTERNOON TEA
15.20 Effective risk-management planning in older people
• Effectiveness of post-authorisation studies
• Important considerations in prescribing
• Predicting adverse drug reactions: Key predictor outcomes
Michael Richardson, VP International and QPPV EU GPV&E,
Bristol Myers Squibb
16.00 The use of body monitoring devices to monitor Geriatric
drug absorption rates
• Body monitoring devices as a useful tool to detect
absorption rates
• Assessment of patient reaction to drug substances
• Body monitoring devices: an effective effective method of
assessing in real-time a patients reaction to dosage forms
Jean Cuine, Chief Scientific Officer, NextPharma
16.40 Chairman’s Closing Remarks and Close of Day Two
Geriatric Safe Medicines Summit
SPONSORSHIP
AND EXHIBITION
OPPORTUNITIES
SMi offer sponsorship,
exhibition, advertising and
branding packages, uniquely
tailored to complement your
company's marketing
strategy. Should you wish to
join the increasing number of
companies benefiting from
sponsoring our conferences
please call:
Anuja Raut, SMi Sponsorship
on +44 20 7827 6128 or
email: araut@smi-online.co.uk
SMi PHARMACEUTICALS FORWARD PLANNER 2013
MAY
Generics, Supergenerics
and Patent Strategies
13 - 14 May 2013, London
Pain Therapeutics
20 - 21 May 2013, London
ADC Summit
20 - 21 May 2013, London
Clinical Trial Logistics
22 - 23 May 2013, London
JUNE
RNAi & Nanotechnology
5 - 6 June 2013, London
Biobanking
24 - 25 June 2013, London
JULY
Pharmacovigilance
1 - 2 July 2013, London
Cell Culture
3 - 4 July 2013, London
ADMET
10 - 11 July 2013, London
SEPTEMBER
Cancer Vaccines
18 - 19 September 2013,
London
OCTOBER
Biosimilars & Biobetters
1 - 2 October 2013, London
Diabetes
1 - 2 October 2013, London
Orphan Drugs
14 - 15 October 2013, London
COPD: Novel Therapeutics
and Management Strategies
16 - 17 October 2013, London
European Pharmaceutical
Pricing & Reimbursement
21 - 22 October 2013, London
Point of Care Diagnostics -
Market Opportunities and
Technology Trents
23 - 24 October 2013, London
NOVEMBER
Cell Based Assays
18 - 19 November 2013,
London
Clinical Trials in CNS
18 - 19 November 2013,
London
DECEMBER
Cold Chain Distribution
3 - 4 December 2013, London
Philippe Guillet, Ageing Therapeutic Strategic Unit, Sanofi
GERIATRIC SAFE MEDICINES SUMMIT
Conference: Monday 16th and Tuesday 17th September 2013, Marriott Hotel, London, UK
4 WAYS TO REGISTER
FAX your booking form to +44 (0) 870 9090 712
PHONE on +44 (0) 870 9090 711
www.geriatricsummit.com
POST your booking form to: Events Team, SMi Group Ltd, 2nd Floor South,
Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email them at events@smi-online.co.uk
Payment: If payment is not made at the time of booking, then an invoice will be issued and must
be paid immediately and prior to the start of the event. If payment has not been received then
credit card details will be requested and payment taken before entry to the event. Bookings within
7 days of event require payment on booking. Access to the Document Portal will not be given until
payment has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another
delegate to take your place at any time prior to the start of the event. Two or more delegates may
not ‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send a
substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing
that cancellation is made in writing and received at least 28 days prior to the start of the event.
Regretfully cancellation after this time cannot be accepted. We will however provide the
conferences documentation via the Document Portal to any delegate who has paid but is unable
to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to
providedocumentationinthesecircumstances.Wecannotacceptcancellationsofordersplaced
forDocumentationortheDocumentPortalasthesearereproducedspecificallytoorder.Ifwehave
to cancel the event for any reason, then we will make a full refund immediately, but disclaim any
further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing,
venue or date of the event compared to the advertised programme.
Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection
Act1998andwemayusethistocontactyoubytelephone,fax,postoremailtotellyouaboutother
productsandservices.Unlessyoutickhere□ wemayalsoshareyourdatawiththirdpartiesoffering
complementary products or services. If you have any queries or want to update any of the data
that we hold then please contact our Database Manager databasemanager@smi-online.co.uk or
visitourwebsitewww.smi-online.co.uk/updatesquotingtheURNasdetailedaboveyouraddresson
the attached letter.
Unique Reference Number
Our Reference LVP-113
Terms and Conditions of Booking
DELEGATE DETAILS
Please complete fully and clearly in capital letters. Please photocopy for additional delegates.
Title: Forename:
Surname:
Job Title:
Department/Division:
Company/Organisation:
Email:
Company VAT Number:
Address:
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Mobile:
Switchboard:
Signature: Date:
I agree to be bound by SMi's Terms and Conditions of Booking.
ACCOUNTS DEPT
Title: Forename:
Surname:
Email:
Address (if different from above):
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Payment must be made to SMi Group Ltd, and received before the event, by one of
the following methods quoting reference P-113 and the delegate’s name. Bookings
made within 7 days of the event require payment on booking, methods of payment
are below. Please indicate method of payment:
□ UK BACS Sort Code 300009, Account 00936418
□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418
IBAN GB48 LOYD 3000 0900 9364 18
□ Cheque We can only accept Sterling cheques drawn on a UK bank.
□ Credit Card □ Visa □ MasterCard □ American Express
All credit card payments will be subject to standard credit card charges.
Card No: □□□□ □□□□ □□□□ □□□□
Valid From □□/□□ Expiry Date □□/□□
CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Cardholder’s Name:
Signature: Date:
I agree to be bound by SMi's Terms and Conditions of Booking.
Card Billing Address (If different from above):
DOCUMENTATION
I cannot attend but would like to purchase access to the following Document
Portal/paper copy documentation Price Total
□ Access to the conference documentation
on the Document Portal £499.00 + VAT £598.80
□ The Conference Presentations – paper copy £499.00 - £499.00
(or only £300 if ordered with the Document Portal)
PAYMENT
VENUE Marriott Hotel Regents Park, 128 King Henry's Road, London, NW3 3ST
□ Please contact me to book my hotel
Alternatively call us on +44 (0) 870 9090 711,
email: hotels@smi-online.co.uk or fax +44 (0) 870 9090 712
□ Book by 31st May to receive a £300 off the conference price
□ Book by 28th June to receive a £100 off the conference price
EARLY BIRD
DISCOUNT
VAT
VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on Document
Portal and Literature Distribution for all UK customers and for those EU customers not supplying
a registration number for their own country here: ______________________________________
CONFERENCE PRICES
I would like to attend: (Please tick as appropriate) Fee Total
□ Conference only £1499.00 + VAT £1798.80
PROMOTIONAL LITERATURE DISTRIBUTION
□ Distribution of your company’s promotional
literature to all conference attendees £999.00 + VAT £1198.80
The conference fee includes refreshments, lunch, conference papers and access
to the Document Portal containing all of the presentations.

More Related Content

What's hot

Sightseeing Pharmacy practice - The way forward
Sightseeing Pharmacy practice - The way forwardSightseeing Pharmacy practice - The way forward
Sightseeing Pharmacy practice - The way forwardinemet
 
Polypharmacy: a UK perspective_Dr Rupert Payne
Polypharmacy: a UK perspective_Dr Rupert PaynePolypharmacy: a UK perspective_Dr Rupert Payne
Polypharmacy: a UK perspective_Dr Rupert PayneHealth Innovation Wessex
 
Melanomabridge 2014_Patient-centered research
Melanomabridge 2014_Patient-centered researchMelanomabridge 2014_Patient-centered research
Melanomabridge 2014_Patient-centered researchBettina Ryll
 
Clinical research training - Deirdre Hyland, RCSI - Dec 7th 2016
Clinical research training - Deirdre Hyland, RCSI - Dec 7th 2016Clinical research training - Deirdre Hyland, RCSI - Dec 7th 2016
Clinical research training - Deirdre Hyland, RCSI - Dec 7th 2016ipposi
 
In Electronic Health Records We Trust - IPPOSI Outcome Report - March 2017
In Electronic Health Records We Trust - IPPOSI Outcome Report - March 2017In Electronic Health Records We Trust - IPPOSI Outcome Report - March 2017
In Electronic Health Records We Trust - IPPOSI Outcome Report - March 2017ipposi
 
The role of patients and healthcare providers in translational medicine
The role of patients and healthcare providers in translational medicineThe role of patients and healthcare providers in translational medicine
The role of patients and healthcare providers in translational medicinejangeissler
 
Presentation for EPEMED Webinar (11-27-12) Final
Presentation for EPEMED Webinar (11-27-12) FinalPresentation for EPEMED Webinar (11-27-12) Final
Presentation for EPEMED Webinar (11-27-12) FinalStig Albinus
 
Clinical Trials Event , Mansion House, Dublin, 10052018
Clinical Trials Event , Mansion House, Dublin, 10052018Clinical Trials Event , Mansion House, Dublin, 10052018
Clinical Trials Event , Mansion House, Dublin, 10052018ipposi
 
2014 07-08 Selectbio Biomarkers 2014, Cambridge
2014 07-08 Selectbio Biomarkers 2014, Cambridge2014 07-08 Selectbio Biomarkers 2014, Cambridge
2014 07-08 Selectbio Biomarkers 2014, CambridgeAlain van Gool
 
Results of an Online Survey of Stakeholders Regarding Barriers and Solutions ...
Results of an Online Survey of Stakeholders Regarding Barriers and Solutions ...Results of an Online Survey of Stakeholders Regarding Barriers and Solutions ...
Results of an Online Survey of Stakeholders Regarding Barriers and Solutions ...John Reites
 
PPPI - the involvement of patients or people in the design and development o...
PPPI -  the involvement of patients or people in the design and development o...PPPI -  the involvement of patients or people in the design and development o...
PPPI - the involvement of patients or people in the design and development o...ipposi
 
Pharmacy Global Track(s)
Pharmacy Global Track(s)Pharmacy Global Track(s)
Pharmacy Global Track(s)inemet
 
Clinical trial recruitment overview
Clinical trial recruitment overviewClinical trial recruitment overview
Clinical trial recruitment overviewUsama Malik
 
Making Value-Based Healthcare in Cataract a Reality Insights from VBHCAT Pr...
Making Value-Based Healthcare in Cataract a Reality  Insights from VBHCAT  Pr...Making Value-Based Healthcare in Cataract a Reality  Insights from VBHCAT  Pr...
Making Value-Based Healthcare in Cataract a Reality Insights from VBHCAT Pr...Alexandre Lourenço
 
Roadmap to-choosing-a-medical-specialty- (1)
Roadmap to-choosing-a-medical-specialty- (1)Roadmap to-choosing-a-medical-specialty- (1)
Roadmap to-choosing-a-medical-specialty- (1)Grupo16011
 

What's hot (20)

Sightseeing Pharmacy practice - The way forward
Sightseeing Pharmacy practice - The way forwardSightseeing Pharmacy practice - The way forward
Sightseeing Pharmacy practice - The way forward
 
Polypharmacy: a UK perspective_Dr Rupert Payne
Polypharmacy: a UK perspective_Dr Rupert PaynePolypharmacy: a UK perspective_Dr Rupert Payne
Polypharmacy: a UK perspective_Dr Rupert Payne
 
Melanomabridge 2014_Patient-centered research
Melanomabridge 2014_Patient-centered researchMelanomabridge 2014_Patient-centered research
Melanomabridge 2014_Patient-centered research
 
Clinical research training - Deirdre Hyland, RCSI - Dec 7th 2016
Clinical research training - Deirdre Hyland, RCSI - Dec 7th 2016Clinical research training - Deirdre Hyland, RCSI - Dec 7th 2016
Clinical research training - Deirdre Hyland, RCSI - Dec 7th 2016
 
Itamar Medical
Itamar MedicalItamar Medical
Itamar Medical
 
In Electronic Health Records We Trust - IPPOSI Outcome Report - March 2017
In Electronic Health Records We Trust - IPPOSI Outcome Report - March 2017In Electronic Health Records We Trust - IPPOSI Outcome Report - March 2017
In Electronic Health Records We Trust - IPPOSI Outcome Report - March 2017
 
The role of patients and healthcare providers in translational medicine
The role of patients and healthcare providers in translational medicineThe role of patients and healthcare providers in translational medicine
The role of patients and healthcare providers in translational medicine
 
Presentation for EPEMED Webinar (11-27-12) Final
Presentation for EPEMED Webinar (11-27-12) FinalPresentation for EPEMED Webinar (11-27-12) Final
Presentation for EPEMED Webinar (11-27-12) Final
 
Clinical Trials Event , Mansion House, Dublin, 10052018
Clinical Trials Event , Mansion House, Dublin, 10052018Clinical Trials Event , Mansion House, Dublin, 10052018
Clinical Trials Event , Mansion House, Dublin, 10052018
 
2014 07-08 Selectbio Biomarkers 2014, Cambridge
2014 07-08 Selectbio Biomarkers 2014, Cambridge2014 07-08 Selectbio Biomarkers 2014, Cambridge
2014 07-08 Selectbio Biomarkers 2014, Cambridge
 
Results of an Online Survey of Stakeholders Regarding Barriers and Solutions ...
Results of an Online Survey of Stakeholders Regarding Barriers and Solutions ...Results of an Online Survey of Stakeholders Regarding Barriers and Solutions ...
Results of an Online Survey of Stakeholders Regarding Barriers and Solutions ...
 
PCORI: Engaging Patients in Clinical Trials & Outcomes Research
PCORI: Engaging Patients in Clinical Trials & Outcomes ResearchPCORI: Engaging Patients in Clinical Trials & Outcomes Research
PCORI: Engaging Patients in Clinical Trials & Outcomes Research
 
PPPI - the involvement of patients or people in the design and development o...
PPPI -  the involvement of patients or people in the design and development o...PPPI -  the involvement of patients or people in the design and development o...
PPPI - the involvement of patients or people in the design and development o...
 
Pharmacy Global Track(s)
Pharmacy Global Track(s)Pharmacy Global Track(s)
Pharmacy Global Track(s)
 
0207 1 Luca Mazzarella - precision medicine
0207 1 Luca Mazzarella - precision medicine0207 1 Luca Mazzarella - precision medicine
0207 1 Luca Mazzarella - precision medicine
 
Clinical trial recruitment overview
Clinical trial recruitment overviewClinical trial recruitment overview
Clinical trial recruitment overview
 
Clinical Trial Recruitment
Clinical Trial RecruitmentClinical Trial Recruitment
Clinical Trial Recruitment
 
1. vbhc event presentatiev2
1. vbhc event presentatiev21. vbhc event presentatiev2
1. vbhc event presentatiev2
 
Making Value-Based Healthcare in Cataract a Reality Insights from VBHCAT Pr...
Making Value-Based Healthcare in Cataract a Reality  Insights from VBHCAT  Pr...Making Value-Based Healthcare in Cataract a Reality  Insights from VBHCAT  Pr...
Making Value-Based Healthcare in Cataract a Reality Insights from VBHCAT Pr...
 
Roadmap to-choosing-a-medical-specialty- (1)
Roadmap to-choosing-a-medical-specialty- (1)Roadmap to-choosing-a-medical-specialty- (1)
Roadmap to-choosing-a-medical-specialty- (1)
 

Viewers also liked

Research & Development - Medical Device Innovation
Research & Development - Medical Device InnovationResearch & Development - Medical Device Innovation
Research & Development - Medical Device InnovationHaroon Abbu
 
I'm not a patient by achilles design
I'm not a patient by achilles designI'm not a patient by achilles design
I'm not a patient by achilles designAchilles Design
 
KEY STAKEHOLDERS IN CLINICAL RESEARCH SUCHISMITA BANIK
KEY STAKEHOLDERS IN CLINICAL RESEARCH SUCHISMITA BANIKKEY STAKEHOLDERS IN CLINICAL RESEARCH SUCHISMITA BANIK
KEY STAKEHOLDERS IN CLINICAL RESEARCH SUCHISMITA BANIKDr. Suchismita Banik
 
Wearable Sensors and UX Development
Wearable Sensors and UX DevelopmentWearable Sensors and UX Development
Wearable Sensors and UX DevelopmentMark Melnykowycz
 
Design and development of medical device
Design and development of medical deviceDesign and development of medical device
Design and development of medical deviceMalesh M
 
Presentation: Life cycle of medical devices
Presentation: Life cycle of medical devicesPresentation: Life cycle of medical devices
Presentation: Life cycle of medical devicesTGA Australia
 
Common Mistakes in the Medical Device Development Continuum
Common Mistakes in the Medical Device Development ContinuumCommon Mistakes in the Medical Device Development Continuum
Common Mistakes in the Medical Device Development ContinuumNAMSA
 
Carolien Creemers & Maarten Bressinck Talk at UX Antwerp Meetup
Carolien Creemers & Maarten Bressinck Talk at UX Antwerp MeetupCarolien Creemers & Maarten Bressinck Talk at UX Antwerp Meetup
Carolien Creemers & Maarten Bressinck Talk at UX Antwerp MeetupUX Antwerp Meetup
 
FDA Design Controls: What Medical Device Makers Need to Know
FDA Design Controls: What Medical Device Makers Need to KnowFDA Design Controls: What Medical Device Makers Need to Know
FDA Design Controls: What Medical Device Makers Need to KnowGreenlight Guru
 
Easy UX Process Steps Must follow by every UX Designer
Easy UX Process Steps Must follow by every UX Designer Easy UX Process Steps Must follow by every UX Designer
Easy UX Process Steps Must follow by every UX Designer Think 360 Studio
 
How UX Design Has Changed The World
How UX Design Has Changed The WorldHow UX Design Has Changed The World
How UX Design Has Changed The WorldBuiltByHQ
 
UX Humor | Jokes and Funny Quotes
UX Humor | Jokes and Funny QuotesUX Humor | Jokes and Funny Quotes
UX Humor | Jokes and Funny QuotesThink 360 Studio
 
Heart sounds and murmur
Heart sounds and murmurHeart sounds and murmur
Heart sounds and murmurVitrag Shah
 

Viewers also liked (13)

Research & Development - Medical Device Innovation
Research & Development - Medical Device InnovationResearch & Development - Medical Device Innovation
Research & Development - Medical Device Innovation
 
I'm not a patient by achilles design
I'm not a patient by achilles designI'm not a patient by achilles design
I'm not a patient by achilles design
 
KEY STAKEHOLDERS IN CLINICAL RESEARCH SUCHISMITA BANIK
KEY STAKEHOLDERS IN CLINICAL RESEARCH SUCHISMITA BANIKKEY STAKEHOLDERS IN CLINICAL RESEARCH SUCHISMITA BANIK
KEY STAKEHOLDERS IN CLINICAL RESEARCH SUCHISMITA BANIK
 
Wearable Sensors and UX Development
Wearable Sensors and UX DevelopmentWearable Sensors and UX Development
Wearable Sensors and UX Development
 
Design and development of medical device
Design and development of medical deviceDesign and development of medical device
Design and development of medical device
 
Presentation: Life cycle of medical devices
Presentation: Life cycle of medical devicesPresentation: Life cycle of medical devices
Presentation: Life cycle of medical devices
 
Common Mistakes in the Medical Device Development Continuum
Common Mistakes in the Medical Device Development ContinuumCommon Mistakes in the Medical Device Development Continuum
Common Mistakes in the Medical Device Development Continuum
 
Carolien Creemers & Maarten Bressinck Talk at UX Antwerp Meetup
Carolien Creemers & Maarten Bressinck Talk at UX Antwerp MeetupCarolien Creemers & Maarten Bressinck Talk at UX Antwerp Meetup
Carolien Creemers & Maarten Bressinck Talk at UX Antwerp Meetup
 
FDA Design Controls: What Medical Device Makers Need to Know
FDA Design Controls: What Medical Device Makers Need to KnowFDA Design Controls: What Medical Device Makers Need to Know
FDA Design Controls: What Medical Device Makers Need to Know
 
Easy UX Process Steps Must follow by every UX Designer
Easy UX Process Steps Must follow by every UX Designer Easy UX Process Steps Must follow by every UX Designer
Easy UX Process Steps Must follow by every UX Designer
 
How UX Design Has Changed The World
How UX Design Has Changed The WorldHow UX Design Has Changed The World
How UX Design Has Changed The World
 
UX Humor | Jokes and Funny Quotes
UX Humor | Jokes and Funny QuotesUX Humor | Jokes and Funny Quotes
UX Humor | Jokes and Funny Quotes
 
Heart sounds and murmur
Heart sounds and murmurHeart sounds and murmur
Heart sounds and murmur
 

Similar to P 113 geriatric

SMi Group's 12th annual Paediatric Clinical Trials 2018
SMi Group's 12th annual Paediatric Clinical Trials 2018SMi Group's 12th annual Paediatric Clinical Trials 2018
SMi Group's 12th annual Paediatric Clinical Trials 2018Dale Butler
 
SMi Group's 9th annual Paediatric Clinical Trials conference
SMi Group's 9th annual Paediatric Clinical Trials conferenceSMi Group's 9th annual Paediatric Clinical Trials conference
SMi Group's 9th annual Paediatric Clinical Trials conferenceDale Butler
 
p-186 Orphan drugs and Rare Diseases
p-186 Orphan drugs and Rare Diseasesp-186 Orphan drugs and Rare Diseases
p-186 Orphan drugs and Rare DiseasesKiran Bains
 
SMi Group's 5th annual Orphan Drugs 2016 conference
SMi Group's 5th annual Orphan Drugs 2016 conferenceSMi Group's 5th annual Orphan Drugs 2016 conference
SMi Group's 5th annual Orphan Drugs 2016 conferenceDale Butler
 
What can we learn from developing medicines information for patients?
What can we learn from developing medicines information for patients?What can we learn from developing medicines information for patients?
What can we learn from developing medicines information for patients?HLGUK
 
SMi Group's 9th annual ADMET conference & exhibition
SMi Group's 9th annual ADMET conference & exhibitionSMi Group's 9th annual ADMET conference & exhibition
SMi Group's 9th annual ADMET conference & exhibitionDale Butler
 
SMi Group's 6th annual COPD conference
SMi Group's 6th annual COPD conferenceSMi Group's 6th annual COPD conference
SMi Group's 6th annual COPD conferenceDale Butler
 
Changes in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical worldChanges in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical worldjangeissler
 
SMi Group's Orphan Drugs conference
SMi Group's Orphan Drugs conferenceSMi Group's Orphan Drugs conference
SMi Group's Orphan Drugs conferenceDale Butler
 
The Role of Patients & their Challenges in Clinical Trials
The Role of Patients & their Challenges in Clinical TrialsThe Role of Patients & their Challenges in Clinical Trials
The Role of Patients & their Challenges in Clinical TrialsKathi Apostolidis
 
SMi Group's Orphan Drugs and Rare Diseases 2019
SMi Group's Orphan Drugs and Rare Diseases 2019SMi Group's Orphan Drugs and Rare Diseases 2019
SMi Group's Orphan Drugs and Rare Diseases 2019Dale Butler
 
Brookman final last 5 nov
Brookman final last 5 nov Brookman final last 5 nov
Brookman final last 5 nov Nowgen
 
Day 1: Challenges and opportunities for better detection, diagnosis and clini...
Day 1: Challenges and opportunities for better detection, diagnosis and clini...Day 1: Challenges and opportunities for better detection, diagnosis and clini...
Day 1: Challenges and opportunities for better detection, diagnosis and clini...KTN
 
UCD PharmTox event on Clinical Trials
UCD PharmTox event on Clinical TrialsUCD PharmTox event on Clinical Trials
UCD PharmTox event on Clinical Trialsipposi
 
Changes in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical worldChanges in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical worldjangeissler
 
SMi Group's 5th annual Drug Safety 2018 conference
SMi Group's 5th annual Drug Safety 2018 conferenceSMi Group's 5th annual Drug Safety 2018 conference
SMi Group's 5th annual Drug Safety 2018 conferenceDale Butler
 

Similar to P 113 geriatric (20)

SMi Group's 12th annual Paediatric Clinical Trials 2018
SMi Group's 12th annual Paediatric Clinical Trials 2018SMi Group's 12th annual Paediatric Clinical Trials 2018
SMi Group's 12th annual Paediatric Clinical Trials 2018
 
SMi Group's 9th annual Paediatric Clinical Trials conference
SMi Group's 9th annual Paediatric Clinical Trials conferenceSMi Group's 9th annual Paediatric Clinical Trials conference
SMi Group's 9th annual Paediatric Clinical Trials conference
 
p-186 Orphan drugs and Rare Diseases
p-186 Orphan drugs and Rare Diseasesp-186 Orphan drugs and Rare Diseases
p-186 Orphan drugs and Rare Diseases
 
SMi Group's 5th annual Orphan Drugs 2016 conference
SMi Group's 5th annual Orphan Drugs 2016 conferenceSMi Group's 5th annual Orphan Drugs 2016 conference
SMi Group's 5th annual Orphan Drugs 2016 conference
 
What can we learn from developing medicines information for patients?
What can we learn from developing medicines information for patients?What can we learn from developing medicines information for patients?
What can we learn from developing medicines information for patients?
 
SMi Group's 9th annual ADMET conference & exhibition
SMi Group's 9th annual ADMET conference & exhibitionSMi Group's 9th annual ADMET conference & exhibition
SMi Group's 9th annual ADMET conference & exhibition
 
SMi Group's 6th annual COPD conference
SMi Group's 6th annual COPD conferenceSMi Group's 6th annual COPD conference
SMi Group's 6th annual COPD conference
 
Changes in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical worldChanges in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical world
 
SMi Group's Orphan Drugs conference
SMi Group's Orphan Drugs conferenceSMi Group's Orphan Drugs conference
SMi Group's Orphan Drugs conference
 
BALS181
BALS181BALS181
BALS181
 
BALS18222
BALS18222BALS18222
BALS18222
 
The Role of Patients & their Challenges in Clinical Trials
The Role of Patients & their Challenges in Clinical TrialsThe Role of Patients & their Challenges in Clinical Trials
The Role of Patients & their Challenges in Clinical Trials
 
SMi Group's Orphan Drugs and Rare Diseases 2019
SMi Group's Orphan Drugs and Rare Diseases 2019SMi Group's Orphan Drugs and Rare Diseases 2019
SMi Group's Orphan Drugs and Rare Diseases 2019
 
Brookman final last 5 nov
Brookman final last 5 nov Brookman final last 5 nov
Brookman final last 5 nov
 
Day 1: Challenges and opportunities for better detection, diagnosis and clini...
Day 1: Challenges and opportunities for better detection, diagnosis and clini...Day 1: Challenges and opportunities for better detection, diagnosis and clini...
Day 1: Challenges and opportunities for better detection, diagnosis and clini...
 
UCD PharmTox event on Clinical Trials
UCD PharmTox event on Clinical TrialsUCD PharmTox event on Clinical Trials
UCD PharmTox event on Clinical Trials
 
Changes in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical worldChanges in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical world
 
Patient involvement
Patient involvementPatient involvement
Patient involvement
 
PEN Awards Webinar – 29 Sept 2015
PEN Awards Webinar – 29 Sept 2015PEN Awards Webinar – 29 Sept 2015
PEN Awards Webinar – 29 Sept 2015
 
SMi Group's 5th annual Drug Safety 2018 conference
SMi Group's 5th annual Drug Safety 2018 conferenceSMi Group's 5th annual Drug Safety 2018 conference
SMi Group's 5th annual Drug Safety 2018 conference
 

More from Yulia Rotar

Border Security - 2014, February, Sofia, Bulgaria
Border Security - 2014, February, Sofia, BulgariaBorder Security - 2014, February, Sofia, Bulgaria
Border Security - 2014, February, Sofia, BulgariaYulia Rotar
 
European smart grid cyber and scada security
European smart grid cyber and scada securityEuropean smart grid cyber and scada security
European smart grid cyber and scada securityYulia Rotar
 
Gas to liquids north america
Gas to liquids north americaGas to liquids north america
Gas to liquids north americaYulia Rotar
 
Pre filled syringes americas
Pre filled syringes americasPre filled syringes americas
Pre filled syringes americasYulia Rotar
 
Biosimilars & biobetters usa
Biosimilars & biobetters usaBiosimilars & biobetters usa
Biosimilars & biobetters usaYulia Rotar
 
Infographic pfs industry survey results
Infographic   pfs industry survey resultsInfographic   pfs industry survey results
Infographic pfs industry survey resultsYulia Rotar
 

More from Yulia Rotar (6)

Border Security - 2014, February, Sofia, Bulgaria
Border Security - 2014, February, Sofia, BulgariaBorder Security - 2014, February, Sofia, Bulgaria
Border Security - 2014, February, Sofia, Bulgaria
 
European smart grid cyber and scada security
European smart grid cyber and scada securityEuropean smart grid cyber and scada security
European smart grid cyber and scada security
 
Gas to liquids north america
Gas to liquids north americaGas to liquids north america
Gas to liquids north america
 
Pre filled syringes americas
Pre filled syringes americasPre filled syringes americas
Pre filled syringes americas
 
Biosimilars & biobetters usa
Biosimilars & biobetters usaBiosimilars & biobetters usa
Biosimilars & biobetters usa
 
Infographic pfs industry survey results
Infographic   pfs industry survey resultsInfographic   pfs industry survey results
Infographic pfs industry survey results
 

Recently uploaded

IIBA® Melbourne - Navigating Business Analysis - Excellence for Career Growth...
IIBA® Melbourne - Navigating Business Analysis - Excellence for Career Growth...IIBA® Melbourne - Navigating Business Analysis - Excellence for Career Growth...
IIBA® Melbourne - Navigating Business Analysis - Excellence for Career Growth...AustraliaChapterIIBA
 
Harvard Business Review.pptx | Navigating Labor Unrest (March-April 2024)
Harvard Business Review.pptx | Navigating Labor Unrest (March-April 2024)Harvard Business Review.pptx | Navigating Labor Unrest (March-April 2024)
Harvard Business Review.pptx | Navigating Labor Unrest (March-April 2024)tazeenaila12
 
BCE24 | Virtual Brand Ambassadors: Making Brands Personal - John Meulemans
BCE24 | Virtual Brand Ambassadors: Making Brands Personal - John MeulemansBCE24 | Virtual Brand Ambassadors: Making Brands Personal - John Meulemans
BCE24 | Virtual Brand Ambassadors: Making Brands Personal - John MeulemansBBPMedia1
 
Boat Trailers Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...
Boat Trailers Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...Boat Trailers Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...
Boat Trailers Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...IMARC Group
 
Intellectual Property Licensing Examples
Intellectual Property Licensing ExamplesIntellectual Property Licensing Examples
Intellectual Property Licensing Examplesamberjiles31
 
Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024Borderless Access
 
ISONIKE Ltd Accreditation for the Conformity Assessment and Certification of ...
ISONIKE Ltd Accreditation for the Conformity Assessment and Certification of ...ISONIKE Ltd Accreditation for the Conformity Assessment and Certification of ...
ISONIKE Ltd Accreditation for the Conformity Assessment and Certification of ...ISONIKELtd
 
Graham and Doddsville - Issue 1 - Winter 2006 (1).pdf
Graham and Doddsville - Issue 1 - Winter 2006 (1).pdfGraham and Doddsville - Issue 1 - Winter 2006 (1).pdf
Graham and Doddsville - Issue 1 - Winter 2006 (1).pdfAnhNguyen97152
 
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdfAMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdfJohnCarloValencia4
 
Borderless Access - Global Panel book-unlock 2024
Borderless Access - Global Panel book-unlock 2024Borderless Access - Global Panel book-unlock 2024
Borderless Access - Global Panel book-unlock 2024Borderless Access
 
Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024Borderless Access
 
PDT 89 - $1.4M - Seed - Plantee Innovations.pdf
PDT 89 - $1.4M - Seed - Plantee Innovations.pdfPDT 89 - $1.4M - Seed - Plantee Innovations.pdf
PDT 89 - $1.4M - Seed - Plantee Innovations.pdfHajeJanKamps
 
Data skills for Agile Teams- Killing story points
Data skills for Agile Teams- Killing story pointsData skills for Agile Teams- Killing story points
Data skills for Agile Teams- Killing story pointsyasinnathani
 
Lecture_6.pptx English speaking easyb to
Lecture_6.pptx English speaking easyb toLecture_6.pptx English speaking easyb to
Lecture_6.pptx English speaking easyb toumarfarooquejamali32
 
A flour, rice and Suji company in Jhang.
A flour, rice and Suji company in Jhang.A flour, rice and Suji company in Jhang.
A flour, rice and Suji company in Jhang.mcshagufta46
 
Borderless Access - Global Panel book-unlock 2024
Borderless Access - Global Panel book-unlock 2024Borderless Access - Global Panel book-unlock 2024
Borderless Access - Global Panel book-unlock 2024Borderless Access
 
Personal Brand Exploration Presentation Eric Bonilla
Personal Brand Exploration Presentation Eric BonillaPersonal Brand Exploration Presentation Eric Bonilla
Personal Brand Exploration Presentation Eric BonillaEricBonilla13
 
MC Heights construction company in Jhang
MC Heights construction company in JhangMC Heights construction company in Jhang
MC Heights construction company in Jhangmcgroupjeya
 
Chapter_Five_The_Rural_Development_Policies_and_Strategy_of_Ethiopia.pptx
Chapter_Five_The_Rural_Development_Policies_and_Strategy_of_Ethiopia.pptxChapter_Five_The_Rural_Development_Policies_and_Strategy_of_Ethiopia.pptx
Chapter_Five_The_Rural_Development_Policies_and_Strategy_of_Ethiopia.pptxesiyasmengesha
 
Talent Management research intelligence_13 paradigm shifts_20 March 2024.pdf
Talent Management research intelligence_13 paradigm shifts_20 March 2024.pdfTalent Management research intelligence_13 paradigm shifts_20 March 2024.pdf
Talent Management research intelligence_13 paradigm shifts_20 March 2024.pdfCharles Cotter, PhD
 

Recently uploaded (20)

IIBA® Melbourne - Navigating Business Analysis - Excellence for Career Growth...
IIBA® Melbourne - Navigating Business Analysis - Excellence for Career Growth...IIBA® Melbourne - Navigating Business Analysis - Excellence for Career Growth...
IIBA® Melbourne - Navigating Business Analysis - Excellence for Career Growth...
 
Harvard Business Review.pptx | Navigating Labor Unrest (March-April 2024)
Harvard Business Review.pptx | Navigating Labor Unrest (March-April 2024)Harvard Business Review.pptx | Navigating Labor Unrest (March-April 2024)
Harvard Business Review.pptx | Navigating Labor Unrest (March-April 2024)
 
BCE24 | Virtual Brand Ambassadors: Making Brands Personal - John Meulemans
BCE24 | Virtual Brand Ambassadors: Making Brands Personal - John MeulemansBCE24 | Virtual Brand Ambassadors: Making Brands Personal - John Meulemans
BCE24 | Virtual Brand Ambassadors: Making Brands Personal - John Meulemans
 
Boat Trailers Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...
Boat Trailers Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...Boat Trailers Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...
Boat Trailers Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...
 
Intellectual Property Licensing Examples
Intellectual Property Licensing ExamplesIntellectual Property Licensing Examples
Intellectual Property Licensing Examples
 
Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024
 
ISONIKE Ltd Accreditation for the Conformity Assessment and Certification of ...
ISONIKE Ltd Accreditation for the Conformity Assessment and Certification of ...ISONIKE Ltd Accreditation for the Conformity Assessment and Certification of ...
ISONIKE Ltd Accreditation for the Conformity Assessment and Certification of ...
 
Graham and Doddsville - Issue 1 - Winter 2006 (1).pdf
Graham and Doddsville - Issue 1 - Winter 2006 (1).pdfGraham and Doddsville - Issue 1 - Winter 2006 (1).pdf
Graham and Doddsville - Issue 1 - Winter 2006 (1).pdf
 
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdfAMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
 
Borderless Access - Global Panel book-unlock 2024
Borderless Access - Global Panel book-unlock 2024Borderless Access - Global Panel book-unlock 2024
Borderless Access - Global Panel book-unlock 2024
 
Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024
 
PDT 89 - $1.4M - Seed - Plantee Innovations.pdf
PDT 89 - $1.4M - Seed - Plantee Innovations.pdfPDT 89 - $1.4M - Seed - Plantee Innovations.pdf
PDT 89 - $1.4M - Seed - Plantee Innovations.pdf
 
Data skills for Agile Teams- Killing story points
Data skills for Agile Teams- Killing story pointsData skills for Agile Teams- Killing story points
Data skills for Agile Teams- Killing story points
 
Lecture_6.pptx English speaking easyb to
Lecture_6.pptx English speaking easyb toLecture_6.pptx English speaking easyb to
Lecture_6.pptx English speaking easyb to
 
A flour, rice and Suji company in Jhang.
A flour, rice and Suji company in Jhang.A flour, rice and Suji company in Jhang.
A flour, rice and Suji company in Jhang.
 
Borderless Access - Global Panel book-unlock 2024
Borderless Access - Global Panel book-unlock 2024Borderless Access - Global Panel book-unlock 2024
Borderless Access - Global Panel book-unlock 2024
 
Personal Brand Exploration Presentation Eric Bonilla
Personal Brand Exploration Presentation Eric BonillaPersonal Brand Exploration Presentation Eric Bonilla
Personal Brand Exploration Presentation Eric Bonilla
 
MC Heights construction company in Jhang
MC Heights construction company in JhangMC Heights construction company in Jhang
MC Heights construction company in Jhang
 
Chapter_Five_The_Rural_Development_Policies_and_Strategy_of_Ethiopia.pptx
Chapter_Five_The_Rural_Development_Policies_and_Strategy_of_Ethiopia.pptxChapter_Five_The_Rural_Development_Policies_and_Strategy_of_Ethiopia.pptx
Chapter_Five_The_Rural_Development_Policies_and_Strategy_of_Ethiopia.pptx
 
Talent Management research intelligence_13 paradigm shifts_20 March 2024.pdf
Talent Management research intelligence_13 paradigm shifts_20 March 2024.pdfTalent Management research intelligence_13 paradigm shifts_20 March 2024.pdf
Talent Management research intelligence_13 paradigm shifts_20 March 2024.pdf
 

P 113 geriatric

  • 1. www.geriatricsummit.com BOOK BY 31ST MAY AND SAVE £300 / BOOK BY 28TH JUNE AND SAVE £100 Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711 FEATURED SPEAKERS:WHY ATTEND THIS EVENT: • Discover the benefits of performing clinical trials in older people • Identify the key challenges and considerations when conducting clinical trials in older people • Address reasons for clinical trial retention difficulties • Discuss how modelling and simulation along with new patient reporting systems support clinical trials in older people • Explore new market gaps and discover new market strategy • Focus on the EMA geriatric medicines strategy • Solange Rohou, Director of Regulatory Affairs, AstraZeneca • Barbro Westerholm, Member of Parliament, Sweden, Liberal Party Novartis • Michael Richardson, VP International and QPPV EU GPV&E, Bristol Myers Squibb • Eva Bredberg, Director Global Clinical Pharmacology, AstraZeneca • Peter Crome, Professor, Department of Primary Care and Population Health, University College London • Anthea Tinker, Professor of Social Gerontology, Kings College London SMi Presents their Inaugural 16 - 17 SEPT 2013Marriott Hotel, Regents Park, London, UK Geriatric Safe Medicines Summit • Florian Von Raison, Global Programme Head, • Nina Barnett, Consultant Pharmacist,Northwest • Philippe Guillet, Chief Geriatrician,TSU Ageing, Sanofi R&D London Hospitals Trust
  • 2. Want to know how you can get involved? Interested in promoting your pharmaceutical services to this market? Contact Margaret Mugema, SMi Marketing on +44 (0) 207 827 6072, or email mmugema@smi-online.co.uk Register online at: www.geriatricsummit.com • Alternatively fax yo • Pharmacovigilance Specialists • QPPV • Consultant Pharmacologist • Recruitment and Retention Managers • Head of Medicine and Society • Medical Advisor WHO SHOULD ATTEND: 08.30 REGISTRATION & COFFEE 09.00 CHAIRMAN’S OPENING REMARKS: Solange Rohou, Director of Regulatory Affairs, AstraZeneca KEY NOTE 09.10 Patient Perspectives on Healthy Ageing • Most important is to be regarded as a resource, to feel needed • Not to meet ageism/age discrimination • Effective and safe treatment when in need Barbro Westerholm, Member of Parliament, Sweden, Liberal Party Increasing the Representation of Older People in Clinical Trials 09:50 Representation of Older People in Clinical Trials: Results and recommendations of the PREDICT Study • The systematic reviews confirmed the continued unjustified exclusion of older people from clinical trials and that clinicians treating older people and other professional believed that older people were disadvantaged as a result • Focus groups held in the 9 participating countries confirmed that older people and their countries supported a more robust system for including older people in clinical trials Peter Crome, Professor, University College London 10.30 MORNING COFFEE 11.00 Why do older people drop out of longitudinal health studies and how can they be encouraged to continue to participate? • The evidence from longitudinal studies abut older people who drop out of studies • A case study of the Whitehall research on drop out including what would encourage participation • A personal perspective on involvement in 3 longitudinal studies Anthea Tinker, Professor of Gerontology, Kings College London Addressing Adherence Issues 11.40 What can we learn from non adherence in the Clinical Trial • Adherence as a key to achieve the therapeutic outcomes • Reasons for non-adherence: a patient perspective • Understanding non-adherence as a source for product enhancement early on Sven Stegemann, Director, Capsugel 12.20 NETWORKING LUNCH 13.30 A coaching approach to medication adherence • Changing the consultation paradigm - the imperatives • Practical and perceptual approaches to adherence • Coaching and medication adherence • Managing short consultations Nina Lee Barnett, Consultant Pharmacist, Older People North West London Hospitals Trust and E&SE England Specialist Pharmacy Services 14.10 Are low treatment uptake rates due to polymorbidity and polymedication issues: perspectives from the osteoporosis treatment gap in France and the UK. • Evolution of guidelines and clinical practices in the management of osteoporosis • Current osteoporosis guidelines and treatment gap • Reasons for treatment decline, uptake and withdrawal Jonathan Guillemot, Gerontologist, Kings College London 14.50 AFTERNOON TEA 15.20 Can elderly people use new technologies to record their own data? • Where are we with ePRO in general, and specifically with elderly? • What is our experience with elderly? • What is to be considered in Clinical Trials with elderly when they have unsupervised data collection? • Case studies Valdo Arnera, General Manager, PHT Corp 16.00 Formulation development of orally disintegrating tablets: An opportunity to address swallowing difficulties in geriatric patients • The formulation approaches used to overcome medication non adherence in geriatric patients and the paradigm of patient-centered dosage forms • The emerging pharmaceutical orally disintegrating dosage forms and their significance in the increasingly ageing society • Various technologies and cost-effective strategies for orally disintegrating tablet formulation • Novel atomic force microscopy applications which provide an insight into molecular aspects of orally disintegrating tablets formulation development Ali Al-Khattawi, Researcher in Pharmaceutical Sciences/Drug Delivery, Aston University 16.40 Chairman’s Closing Remarks and Close of Day One • Program Heads • Clinical Trial Design Manager • Gerontologists • Geriatrician • Clinical Trials Manager • Academics DAY ONE | 16TH SEPTEMBER 2013 Geriatric Safe Medicines Summit Supported by • Research Scientists • Pharmaceutical regulators • Stakeholders and those with an interest in Geriatric medicine
  • 3. our registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711 DAY TWO | 17TH SEPTEMBER 2013 08.30 REGISTRATION & COFFEE 09.00 CHAIRMAN’S OPENING REMARKS: Solange Rohou, Director of Regulatory Affairs, AstraZeneca Improving Safety Within Geriatric Clinical Trials 09.10 Geriatric Syndromes: What are they? Why do they matter? • Old Old Adults (75+) is the fastest growing segment of population • Old Old subject to specific Geriatric Syndromes (Frailty, Delirium,...), which change the way acute situations manifest themselves (including drug effects and toxicities), needing specific screening, diagnosis & treatment approaches 09.50 Modelling & simulation to support evaluation of safety and efficacy of drugs in older patients • Strategic considerations in drug development regarding the elderly • Changes in PK and PD with age • What value can M&S provide to improve understanding of risk benefits in older people? • Two examples from AstraZeneca Eva Bredberg, Director Global Clinical Pharmacology, AstraZeneca 10.30 MORNING COFFEE 11.00 What has been done since the revision of the ICH E7 guideline? The Companies' view • The revision of ICH E7 • EFPIA interactions at the workshop organised by the EMA in March 2012 • How to optimise clincial development in the elderly? • What companies are planning/doing to collect data in this special growing population Solange Rohou, Director Regulatory Affairs, AstraZeneca 11.40 Early identification of co-morbidities and the challenges of prescribing in this patient population due to drug- drug interactions • Cognitive impairment as a barrier to treatment • The impact of co-mobidities on a Clinical Trial • Developing effective patient reporting systems as a way to improve patient compliance Mark Baxter, Geriatric Consultant, Spire Sussex Hospital 12.20 NETWORKING LUNCH Importance of Guidance on Medical Research in Geriatric Patients 13.30 Proposal for guidance on medical research for and with older people in Europe • There is an evident lack of consistent ethical guidance on medical research for and with older people in Europe • Workshops with stakeholders from academia, investigators, patient representatives and pharma were held to develop a consensus on principals • The aim of the guidance is to facilitate clinical research for and with the older patient population Florian Von Raison, Global Program Head, Novartis Pharma 14.10 Information for rational drug prescribing to older patients - from pre-authorisation to post-marketing • Older patients in pre-authorisation trials – number, exclusion criteria and representability • Available information for adequate prescribing to older patients – product information and handbooks • What information for adequate prescribing about older patients is needed? – views of clinical and non-clinical professionals Erna Beers, MD, Clinical Pharmacologist, UMC Utrecht 14.50 AFTERNOON TEA 15.20 Effective risk-management planning in older people • Effectiveness of post-authorisation studies • Important considerations in prescribing • Predicting adverse drug reactions: Key predictor outcomes Michael Richardson, VP International and QPPV EU GPV&E, Bristol Myers Squibb 16.00 The use of body monitoring devices to monitor Geriatric drug absorption rates • Body monitoring devices as a useful tool to detect absorption rates • Assessment of patient reaction to drug substances • Body monitoring devices: an effective effective method of assessing in real-time a patients reaction to dosage forms Jean Cuine, Chief Scientific Officer, NextPharma 16.40 Chairman’s Closing Remarks and Close of Day Two Geriatric Safe Medicines Summit SPONSORSHIP AND EXHIBITION OPPORTUNITIES SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company's marketing strategy. Should you wish to join the increasing number of companies benefiting from sponsoring our conferences please call: Anuja Raut, SMi Sponsorship on +44 20 7827 6128 or email: araut@smi-online.co.uk SMi PHARMACEUTICALS FORWARD PLANNER 2013 MAY Generics, Supergenerics and Patent Strategies 13 - 14 May 2013, London Pain Therapeutics 20 - 21 May 2013, London ADC Summit 20 - 21 May 2013, London Clinical Trial Logistics 22 - 23 May 2013, London JUNE RNAi & Nanotechnology 5 - 6 June 2013, London Biobanking 24 - 25 June 2013, London JULY Pharmacovigilance 1 - 2 July 2013, London Cell Culture 3 - 4 July 2013, London ADMET 10 - 11 July 2013, London SEPTEMBER Cancer Vaccines 18 - 19 September 2013, London OCTOBER Biosimilars & Biobetters 1 - 2 October 2013, London Diabetes 1 - 2 October 2013, London Orphan Drugs 14 - 15 October 2013, London COPD: Novel Therapeutics and Management Strategies 16 - 17 October 2013, London European Pharmaceutical Pricing & Reimbursement 21 - 22 October 2013, London Point of Care Diagnostics - Market Opportunities and Technology Trents 23 - 24 October 2013, London NOVEMBER Cell Based Assays 18 - 19 November 2013, London Clinical Trials in CNS 18 - 19 November 2013, London DECEMBER Cold Chain Distribution 3 - 4 December 2013, London Philippe Guillet, Ageing Therapeutic Strategic Unit, Sanofi
  • 4. GERIATRIC SAFE MEDICINES SUMMIT Conference: Monday 16th and Tuesday 17th September 2013, Marriott Hotel, London, UK 4 WAYS TO REGISTER FAX your booking form to +44 (0) 870 9090 712 PHONE on +44 (0) 870 9090 711 www.geriatricsummit.com POST your booking form to: Events Team, SMi Group Ltd, 2nd Floor South, Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email them at events@smi-online.co.uk Payment: If payment is not made at the time of booking, then an invoice will be issued and must be paid immediately and prior to the start of the event. If payment has not been received then credit card details will be requested and payment taken before entry to the event. Bookings within 7 days of event require payment on booking. Access to the Document Portal will not be given until payment has been received. Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another delegate to take your place at any time prior to the start of the event. Two or more delegates may not ‘share’ a place at an event. Please make separate bookings for each delegate. Cancellation: If you wish to cancel your attendance at an event and you are unable to send a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing that cancellation is made in writing and received at least 28 days prior to the start of the event. Regretfully cancellation after this time cannot be accepted. We will however provide the conferences documentation via the Document Portal to any delegate who has paid but is unable to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to providedocumentationinthesecircumstances.Wecannotacceptcancellationsofordersplaced forDocumentationortheDocumentPortalasthesearereproducedspecificallytoorder.Ifwehave to cancel the event for any reason, then we will make a full refund immediately, but disclaim any further liability. Alterations: It may become necessary for us to make alterations to the content, speakers, timing, venue or date of the event compared to the advertised programme. Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection Act1998andwemayusethistocontactyoubytelephone,fax,postoremailtotellyouaboutother productsandservices.Unlessyoutickhere□ wemayalsoshareyourdatawiththirdpartiesoffering complementary products or services. If you have any queries or want to update any of the data that we hold then please contact our Database Manager databasemanager@smi-online.co.uk or visitourwebsitewww.smi-online.co.uk/updatesquotingtheURNasdetailedaboveyouraddresson the attached letter. Unique Reference Number Our Reference LVP-113 Terms and Conditions of Booking DELEGATE DETAILS Please complete fully and clearly in capital letters. Please photocopy for additional delegates. Title: Forename: Surname: Job Title: Department/Division: Company/Organisation: Email: Company VAT Number: Address: Town/City: Post/Zip Code: Country: Direct Tel: Direct Fax: Mobile: Switchboard: Signature: Date: I agree to be bound by SMi's Terms and Conditions of Booking. ACCOUNTS DEPT Title: Forename: Surname: Email: Address (if different from above): Town/City: Post/Zip Code: Country: Direct Tel: Direct Fax: Payment must be made to SMi Group Ltd, and received before the event, by one of the following methods quoting reference P-113 and the delegate’s name. Bookings made within 7 days of the event require payment on booking, methods of payment are below. Please indicate method of payment: □ UK BACS Sort Code 300009, Account 00936418 □ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU Swift (BIC): LOYDGB21013, Account 00936418 IBAN GB48 LOYD 3000 0900 9364 18 □ Cheque We can only accept Sterling cheques drawn on a UK bank. □ Credit Card □ Visa □ MasterCard □ American Express All credit card payments will be subject to standard credit card charges. Card No: □□□□ □□□□ □□□□ □□□□ Valid From □□/□□ Expiry Date □□/□□ CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card Cardholder’s Name: Signature: Date: I agree to be bound by SMi's Terms and Conditions of Booking. Card Billing Address (If different from above): DOCUMENTATION I cannot attend but would like to purchase access to the following Document Portal/paper copy documentation Price Total □ Access to the conference documentation on the Document Portal £499.00 + VAT £598.80 □ The Conference Presentations – paper copy £499.00 - £499.00 (or only £300 if ordered with the Document Portal) PAYMENT VENUE Marriott Hotel Regents Park, 128 King Henry's Road, London, NW3 3ST □ Please contact me to book my hotel Alternatively call us on +44 (0) 870 9090 711, email: hotels@smi-online.co.uk or fax +44 (0) 870 9090 712 □ Book by 31st May to receive a £300 off the conference price □ Book by 28th June to receive a £100 off the conference price EARLY BIRD DISCOUNT VAT VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on Document Portal and Literature Distribution for all UK customers and for those EU customers not supplying a registration number for their own country here: ______________________________________ CONFERENCE PRICES I would like to attend: (Please tick as appropriate) Fee Total □ Conference only £1499.00 + VAT £1798.80 PROMOTIONAL LITERATURE DISTRIBUTION □ Distribution of your company’s promotional literature to all conference attendees £999.00 + VAT £1198.80 The conference fee includes refreshments, lunch, conference papers and access to the Document Portal containing all of the presentations.